MRTX849 Inhibitor

Name: MRTX849 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5759173
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759173

MRTX849 is a potent, selective, and covalent KRASG12C inhibitor with potential antineoplastic activity.selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signaling More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

MRTX849, Inhibitor

Full Product Name

MRTX849

Product Gene Name

MRTX849, inhibitor

Form/Format

Solid. Powder

Purity/Purification

99.90%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

604.12

Solubility

DMSO: 100mg/mL (165.53mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C32H35ClFN7O2

SMILES

CN1CCC[C@H]1COc1nc2CN(CCc2c(n1)N1CCN([C@@H](CC#N)C1)C(=O)C(F)=C)c1cccc2cccc(Cl)c12

CAS Number

2326521-71-3

Target & IC50

KRAS G12C

In Vitro

MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRASG12C-positive cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been observed in patients with KRASG12C-positive lung and colon adenocarcinomas[1].

Product Categories/Family for MRTX849, inhibitor

MAPK; Ras; GPCR/G Protein

Product References and Citations for MRTX849, inhibitor

Jill Hallin, Lars D Engstrom, Lauren Hargis. The KRAS G12C Inhibitor MRTX849 Provides Insight Toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov. 2020 Jan;10(1):54-7
Jill Hallin, Lars D Engstrom, Lauren Hargis. The KRAS G12C Inhibitor MRTX849 Provides Insight Toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov. 2020 Jan;10(1):54-71.
Jay B Fell, John P Fischer, Brian R Baer.Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS G12C Inhibitor for the treatment,of Cancer.J Med Chem. 2020 Apr 6.
Jay B Fell, John P Fischer, Brian R Baer.Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS G12C Inhibitor for the treatment,of Cancer.J Med Chem. 2020 Apr 6.

Other Notes

Small volumes of MRTX849, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for MRTX849 purchase

MBS5759173 is an inhibitor targeting MRTX849.